Biocytogen Pharmaceuticals (Beijing) Balance Sheet Health
Financial Health criteria checks 3/6
Biocytogen Pharmaceuticals (Beijing) has a total shareholder equity of CN¥838.6M and total debt of CN¥402.0M, which brings its debt-to-equity ratio to 47.9%. Its total assets and total liabilities are CN¥2.4B and CN¥1.6B respectively. Biocytogen Pharmaceuticals (Beijing)'s EBIT is CN¥150.2M making its interest coverage ratio 1.8. It has cash and short-term investments of CN¥411.1M.
Key information
47.93%
Debt to equity ratio
CN¥401.97m
Debt
| Interest coverage ratio | 1.8x |
| Cash | CN¥411.10m |
| Equity | CN¥838.60m |
| Total liabilities | CN¥1.58b |
| Total assets | CN¥2.42b |
Recent financial health updates
Health Check: How Prudently Does Biocytogen Pharmaceuticals (Beijing) (HKG:2315) Use Debt?
Dec 12
Is Biocytogen Pharmaceuticals (Beijing) (HKG:2315) A Risky Investment?
May 08Recent updates
We Think Biocytogen Pharmaceuticals (Beijing)'s (HKG:2315) Robust Earnings Are Conservative
May 01Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s (HKG:2315) Price Is Right But Growth Is Lacking After Shares Rocket 91%
Mar 27Health Check: How Prudently Does Biocytogen Pharmaceuticals (Beijing) (HKG:2315) Use Debt?
Dec 12Is Biocytogen Pharmaceuticals (Beijing) (HKG:2315) A Risky Investment?
May 08Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s (HKG:2315) Price Is Right But Growth Is Lacking
Apr 03Financial Position Analysis
Short Term Liabilities: 2315's short term assets (CN¥816.5M) exceed its short term liabilities (CN¥534.9M).
Long Term Liabilities: 2315's short term assets (CN¥816.5M) do not cover its long term liabilities (CN¥1.0B).
Debt to Equity History and Analysis
Debt Level: 2315 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 2315's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 2315's debt is well covered by operating cash flow (52.6%).
Interest Coverage: 2315's interest payments on its debt are not well covered by EBIT (1.8x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/21 16:17 |
| End of Day Share Price | 2025/05/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | CMB International Securities Limited |
| Ziyi Chen | Goldman Sachs |
| Kehan Meng | Haitong International Research Limited |